All participants enrolled in the first phase of the iPrEx study were invited to continue in the Open Label Extension. Those participants who are HIV-negative were offered daily oral PrEP with Truvada through iPrEx OLE. Participants who chose not to take PrEP could remain in the study and receive all the benefits of study participation.
iPrEx participants who were HIV-positive received regular medical monitoring and other services through iPrEx OLE, but will not receive the study drug, which is designed to prevent HIV infection.
|Rio de Janeiro|